SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback